Executive Employment AgreementExecutive Employment Agreement • March 2nd, 2015 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 2nd, 2015 Company Industry JurisdictionARIAD Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Thomas J. DesRosier (the “Employee”) enter into the following Executive Employment Agreement as of the 20th day of January, 2015 (hereafter, the “Agreement”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • March 2nd, 2015 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 2nd, 2015 Company Industry JurisdictionThis Amended and Restated License Agreement (this “Agreement”) is made effective as of March 7, 2011 (the “Effective Date”) by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“ARIAD”), and Bellicum Pharmaceuticals, Inc., a Delaware corporation with a place of business at 6400 Fannin St., Suite 2300, Houston, TX 77030 (“Bellicum”). ARIAD and Bellicum are each hereafter referred to individually as a “Party” and together as the “Parties”.
COLLABORATION AGREEMENT between ARIAD Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., LtdCollaboration Agreement • March 2nd, 2015 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 2nd, 2015 Company Industry JurisdictionTHIS COLLABORATION AGREEMENT (“Agreement”) is effective as of December 22, 2014 (hereinafter called “Effective Date”), between ARIAD Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 26 Landsdowne Street, Cambridge, Massachusetts 02139-4234, USA (“ARIAD”) and Otsuka Pharmaceutical Co., Ltd, a corporation organised and existing under the law of Japan with a principal place of business at Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-Ku, Tokyo 108-8242, Japan (“Otsuka”).
OMNIBUS AMENDMENT AGREEMENTOmnibus Amendment Agreement • March 2nd, 2015 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 2nd, 2015 Company Industry JurisdictionTHIS OMNIBUS AMENDMENT AGREEMENT (“Agreement”) is entered into and made effective as of October 3, 2014 (the “Effective Date”) by and between ARIAD PHARMACEUTICALS, INC., a Delaware corporation with its principal place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“ARIAD”), and BELLICUM PHARMACEUTICALS, INC., a Delaware corporation with a place of business at 2130 Holcombe Boulevard, Suite 850, Houston, TX 77030 (“Bellicum”). ARIAD and Bellicum may be referred to herein individually as a “Party” and collectively as “Parties.”